Vancomycin Research Dosage: Published Protocol Reference
Vancomycin dosage references vary by route and study context. The database lists Intravenous: 15-20 mg/kg, Every 8-12 hours, Oral: 125-500 mg, Four times daily for 10-14 days, and Intravenous (loading dose): 25-30 mg/kg, Once (then standard dosing). These are research-context references, not a universal protocol.
Direct Answer
Vancomycin is FDA-approved and remains the gold standard for MRSA treatment and serious gram-positive infections where beta-lactams are contraindicated. With decades of clinical data, well-established PK/PD targets, and consistent Phase 3 evidence, it is one of the most validated antibiotics in medicine. For gram-positive infection research, vancomycin is the reference compound.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Immune Support
- Best for
- MRSA infections, serious gram-positive infections, C. difficile colitis (oral), beta-lactam-resistant infections
Research Dosage References
- <strong>Intravenous</strong> - 15-20 mg/kg - Every 8-12 hours - Standard dosing for serious infections. Target trough of 15-20 mcg/mL for serious infections; AUC/MIC-guided dosing now preferred. Infuse over at least 60 minutes.
- <strong>Oral</strong> - 125-500 mg - Four times daily for 10-14 days - Oral vancomycin is NOT absorbed systemically. Used exclusively for C. difficile colitis. Acts locally in the GI tract.
- <strong>Intravenous (loading dose)</strong> - 25-30 mg/kg - Once (then standard dosing) - Loading dose for critically ill patients to achieve therapeutic levels rapidly. Maximum single dose typically 3000 mg.
Half-Life
~4-6 hours (significantly prolonged in renal impairment, up to 7.5 days in anuria).
Evidence Limits
Dosage entries are compiled from labels, published studies, and research-context references where available. For Vancomycin, the evidence grade is Level A, and the current research status is FDA Approved.
Safety Signals
- Requires therapeutic drug monitoring (trough levels or AUC-guided dosing)
- Dose adjustment essential in renal impairment
- Ototoxicity risk increases with concomitant ototoxic drugs
- Vancomycin-resistant enterococci (VRE) are an emerging clinical concern
- Infuse over at least 60 minutes to prevent red man syndrome
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | MRSA Infection Treatment (Level A), C. difficile Infection (Oral) (Level A), Nephrotoxicity (Adverse) (Level A), and Red Man Syndrome (Adverse) (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Vancomycin Research Dosage: Published Protocol Reference." Last reviewed 2026-04-04. https://examinepeptides.com/answers/vancomycin-research-dosage/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.